Arvinas, Inc

ARVNNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
8.01 USD
↘ 0.02 (0.25%)AT CLOSE (11:59 AM EDT)
8.00
↘ 0.01 (0.06%)
POST MARKET (AS OF 04:15 PM EDT)
Post Market
AS OF 04:15 PM EDT
8.00
↘ 0.01 (0.06%)
🔴Market: CLOSED

Shares of Arvinas, Inc (ARVN) are trading at $8.01. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, ARVN trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jul 17, 2026.

Open?$7.95
High?$8.18
Low?$7.90
Prev. Close?$8.03
Volume?519.9K
Avg. Volume?780.1K
VWAP?$8.07
Rel. Volume?0.67x
Bid / Ask
Bid?$6.88 × 100
Ask?$9.47 × 100
Spread?$2.59
Midpoint?$8.18
Valuation & Ratios
Market Cap?518.1M
Shares Out?64.5M
Float?52.0M
Float %?80.6%
P/E Ratio?N/A
P/B Ratio?1.34
EPS?-$3.43
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
246
Market Cap
518.1M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.arvinas.com
Listed
2018-09-27
Address
395 WINCHESTER AVE
NEW HAVEN, CT 06511
Phone: 203-535-1456
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
50
Short Sent.?
45
Piotroski F-Score?3/9Weak
Altman Z-Score?-2.62Distress
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?8.21%Elevated
Short Interest?4.3M
Days to Cover?4.6
Free Float52.0M
Avg Daily Volume930.4K
Settlement Date2026-06-30
Financial Health
Current Ratio?5.44Strong
Quick Ratio?5.44Strong
Cash Ratio?0.75Adequate
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
91
1.34CHEAP▾
P/S?
Peers
100
S&P
23
5.80FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.7CHEAP▾
EV/Sales?
Peers
100
S&P
37
4.82FAIR▾
Returns & Efficiency
ROE?
S&P
3
-57.2%WEAK▾
ROA?
S&P
3
-34.2%WEAK▾
Cash Flow & Enterprise
FCF?$-256900000
Enterprise Value?$431.1M
Fundamentals ratios updated end of day
MarketsMoversWatchlist